Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.

被引：0
|
作者：
Bello, Carlo [1 ]
Brar, Satjit [1 ]
Masters, Joanna C. [2 ]
Khandelwal, Akash [3 ]
Novakovic, Ana M. [3 ]
Ruiz-Garcia, Ana [1 ]
Hibma, Jennifer [2 ]
机构：
[1] Pfizer Inc, San Diego, CA USA
[2] Pfizer Inc, La Jolla, CA USA
[3] Merck KGaA, Darmstadt, Germany
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
    Atkins, M. B.
    Plimack, E. R.
    Puzanov, I.
    Fishman, M. N.
    McDermott, D.
    Cho, D. C.
    Vaishampayan, U.
    George, S.
    Olencki, T.
    Tarazi, J.
    Rosbrook, B.
    Fernandez, K.
    Keefe, S.
    Choueiri, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Avelumab D axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
    Choueiri, T. K.
    Penkov, K.
    Uemura, H.
    Campbell, M. T.
    Pal, S.
    Kollmannsberger, C.
    Lee, J. L.
    Venugopal, B.
    Eertwegh, A. J. M. van den
    Negrier, S.
    Gurney, H.
    Albiges, L.
    Berger, R.
    Haanen, J. B. A. G.
    Juarez, V. Oyervides
    Rini, B. I.
    Larkin, J.
    Nole, F.
    Schmidinger, M.
    Atkins, M. B.
    Tomita, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Sandner, R.
    Wang, J.
    di Pietro, A.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2025, 36 (04) : 387 - 392
  • [23] Efficacy of avelumab plus axitinib (A plus Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial
    Eto, M.
    Motzer, R. J.
    Choueiri, T. K.
    Haanen, J. B. A. G.
    Oya, M.
    Uemura, H.
    Venugopal, B.
    Rini, B. I.
    Miyake, H.
    Albiges, L.
    Schmidinger, M.
    Tomita, Y.
    Umeyama, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1512 - S1513
  • [24] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
    Choueiri, Toni K.
    Rini, Brian I.
    Larkin, James M. G.
    Bjarnason, Georg A.
    Gravis, Gwenaelle
    Gurney, Howard
    Lee, Jae-Lyun
    Keizman, Daniel
    Haanen, John B. A. G.
    Tomita, Yoshihiko
    Uemura, Hirotsugu
    Albiges, Laurence
    Schmidinger, Manuela
    Atkins, Michael B.
    Mariani, Mariangela
    Shnaidman, Michael
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S)
    Choueiri, T. K.
    Larkin, J. M. G.
    Pal, S. K.
    Motzer, R. J.
    Venugopal, B.
    Alekseev, B. Y.
    Miyake, H.
    Gravis, G.
    Bilen, M. A.
    Chudnovsky, A.
    Ching, K. A.
    Mariani, M.
    Robbins, P. B.
    Huang, B.
    di Pietro, A.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 361 - 361
  • [26] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Choueiri, T.
    Larkin, J.
    Albiges, L.
    Haanen, J. B.
    Schmidinger, M.
    Atkins, M. B.
    Mariani, M.
    Shnaidman, M.
    Di Pietro, A.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
    Haanen, J. B. A. G.
    Larkin, J.
    Choueiri, T. K.
    Albiges, L.
    Rini, B. I.
    Atkins, M. B.
    Schmidinger, M.
    Penkov, K.
    Michelon, E.
    Wang, J.
    Mariani, M.
    di Pietro, A.
    Motzer, R. J.
    ESMO OPEN, 2023, 8 (03)
  • [28] Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Puzanov, Igor
    Fishman, Mayer N.
    McDermott, David F.
    Cho, Daniel C.
    Vaishampayan, Ulka N.
    George, Saby
    Olencki, Thomas
    Tarazi, Jamal Christo
    Rosbrook, Brad
    Fernandez, Kathrine C.
    Lechuga, Mariajose
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
    Tomita, Y.
    Larkin, J.
    Venugopal, B.
    Haanen, J.
    Kanayama, H.
    Eto, M.
    Grimm, M-O
    Fujii, Y.
    Umeyama, Y.
    Huang, B.
    Mariani, M.
    di Pietro, A.
    Choueiri, T. K.
    ESMO OPEN, 2022, 7 (05)
  • [30] Outcomes of patients who progressed while receiving avelumab plus axitinib (A plus Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.
    Albiges, Laurence
    Voss, Martin H.
    Rini, Brian I.
    Gravis, Gwenaelle
    Grimm, Marc-Oliver
    Nathan, Paul D.
    Bjarnason, Georg A.
    Tomita, Yoshihiko
    Penkov, Konstantin
    McGregor, Bradley
    Huang, Bo
    Thomaidou, Despina
    Mariani, Mariangela
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345